AR positive
|
Salivary Gland Cancer
|
AR positive
|
Salivary Gland Cancer
|
leuprolide acetate Sensitive: A2 - Guideline
|
leuprolide acetate Sensitive: A2 - Guideline
|
AR positive
|
Salivary Gland Cancer
|
AR positive
|
Salivary Gland Cancer
|
bicalutamide Sensitive: A2 - Guideline
|
bicalutamide Sensitive: A2 - Guideline
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
darolutamide Sensitive: C2 – Inclusion Criteria
|
darolutamide Sensitive: C2 – Inclusion Criteria
|
AR positive
|
Breast Cancer
|
AR positive
|
Breast Cancer
|
GT0918 Sensitive: C2 – Inclusion Criteria
|
GT0918 Sensitive: C2 – Inclusion Criteria
|
AR positive
|
Salivary Gland Cancer
|
AR positive
|
Salivary Gland Cancer
|
leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials
|
leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
AR positive
|
Estrogen Receptor Positive Breast Cancer
|
AR positive
|
Estrogen Receptor Positive Breast Cancer
|
enobosarm Sensitive: C3 – Early Trials
|
enobosarm Sensitive: C3 – Early Trials
|
AR positive
|
Salivary Gland Cancer
|
AR positive
|
Salivary Gland Cancer
|
abiraterone acetate Sensitive: C3 – Early Trials
|
abiraterone acetate Sensitive: C3 – Early Trials
|
AR positive
|
Ovarian Cancer
|
AR positive
|
Ovarian Cancer
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
AR positive
|
Prostate Cancer
|
AR positive
|
Prostate Cancer
|
XY123 Sensitive: C4 – Case Studies
|
XY123 Sensitive: C4 – Case Studies
|
AR positive
|
Urothelial Cancer
|
AR positive
|
Urothelial Cancer
|
silodosin Resistant: D – Preclinical
|
silodosin Resistant: D – Preclinical
|
AR positive
|
Breast Cancer
|
AR positive
|
Breast Cancer
|
FT-6876 Sensitive: D – Preclinical
|
FT-6876 Sensitive: D – Preclinical
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
apalutamide Sensitive: D – Preclinical
|
apalutamide Sensitive: D – Preclinical
|
AR positive
|
Prostate Cancer
|
AR positive
|
Prostate Cancer
|
abemaciclib Sensitive: D – Preclinical
|
abemaciclib Sensitive: D – Preclinical
|
AR positive
|
Prostate Cancer
|
AR positive
|
Prostate Cancer
|
GT0918 Sensitive: D – Preclinical
|
GT0918 Sensitive: D – Preclinical
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
HC-1119 Sensitive: D – Preclinical
|
HC-1119 Sensitive: D – Preclinical
|